Thrivent Financial for Lutherans
TEVA icon

Thrivent Financial for Lutherans’s Teva Pharmaceuticals TEVA Stock Holding History

Thrivent Financial for Lutherans’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$896K Buy
29,960
+2,353
+9% +$75.7K ﹤0.01% 1947
2025
Q4 		$862K Sell
27,607
-171,860
-86% -$4.23M ﹤0.01% 2013
2025
Q3 		$4.03M Buy
+199,467
New +$3.5M 0.01% 943
2025
Q1 		– Sell
-225,210
Closed -$4.96M – 2538
2024
Q4 		$4.96M Buy
225,210
+699
+0.3% +$12.7K 0.01% 911
2024
Q3 		$4.05M Buy
224,511
+40,218
+22% +$704K 0.01% 1024
2024
Q2 		$3M Buy
184,293
+56,388
+44% +$869K 0.01% 1135
2024
Q1 		$1.8M Buy
127,905
+114,886
+882% +$1.45M ﹤0.01% 1489
2023
Q4 		$136K Buy
13,019
+283
+2% +$2.64K ﹤0.01% 2453
2023
Q3 		$130K Buy
12,736
+766
+6% +$7.13K ﹤0.01% 2406
2023
Q2 		$90K Hold
11,970
– – ﹤0.01% 2438
2023
Q1 		$106K Buy
11,970
+220
+2% +$2.17K ﹤0.01% 2415
2022
Q4 		$107K Buy
11,750
+252
+2% +$2.2K ﹤0.01% 2383
2022
Q3 		$93K Buy
11,498
+330
+3% +$2.92K ﹤0.01% 2382
2022
Q2 		$84K Buy
11,168
+325
+3% +$2.83K ﹤0.01% 2390
2022
Q1 		$102K Buy
10,843
+177
+2% +$1.48K ﹤0.01% 2476
2021
Q4 		$85K Buy
10,666
+247
+2% +$2.23K ﹤0.01% 2446
2021
Q3 		$101K Buy
10,419
+267
+3% +$2.5K ﹤0.01% 2451
2021
Q2 		$100K Buy
+10,152
New +$107K ﹤0.01% 2433
2019
Q2 		– Sell
-197,500
Closed -$3.1M – 2202
2019
Q1 		$3.1M Hold
197,500
– – 0.01% 797
2018
Q4 		$3.04M Hold
197,500
– – 0.01% 726
2018
Q3 		$4.25M Buy
197,500
+30,000
+18% +$696K 0.01% 690
2018
Q2 		$4.07M Buy
167,500
+134,016
+400% +$2.73M 0.01% 703
2018
Q1 		$572K Buy
+33,484
New +$654K ﹤0.01% 1579
2017
Q4 		– Sell
-72
Closed -$1K – 2278
2017
Q3 		$1K Sell
72
-142,348
-100% -$3.2M ﹤0.01% 2348
2017
Q2 		$4.73M Hold
142,420
– – 0.02% 595
2017
Q1 		$4.57M Buy
142,420
+31,300
+28% +$1.07M 0.02% 603
2016
Q4 		$4.03M Buy
111,120
+110,650
+23,543% +$4.42M 0.02% 647
2016
Q3 		$21K Hold
470
– – ﹤0.01% 1920
2016
Q2 		$24K Hold
470
– – ﹤0.01% 1928
2016
Q1 		$26K Hold
470
– – ﹤0.01% 1894
2015
Q4 		$31K Buy
+470
New +$29K ﹤0.01% 1878
2015
Q3 		– Sell
-470
Closed -$29K – 1861
2015
Q2 		$29K Hold
470
– – ﹤0.01% 1740
2015
Q1 		$31K Hold
470
– – ﹤0.01% 1716
2014
Q4 		$27K Sell
470
-33
-7% -$1.84K ﹤0.01% 1736
2014
Q3 		$27K Buy
+503
New +$26.6K ﹤0.01% 1743
2014
Q1 		– Sell
-53,800
Closed -$2.16M – 1584
2013
Q4 		$2.16M Hold
53,800
– – 0.01% 585
2013
Q3 		$2.03M Hold
53,800
– – 0.01% 581
2013
Q2 		$2.11K Buy
+53,800
New +$2.1M 0.01% 562

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans's TEVA Position: Q1 2026 in Review

Thrivent Financial for Lutherans increased its Teva Pharmaceuticals (TEVA) stake by 8.5% in Q1 2026, buying an estimated $75.7K and bringing the position to 29,960 shares worth $896K. The position accounts for ﹤0.01% of the portfolio, ranked #1947.

Thrivent Financial for Lutherans first reported a position in TEVA in Q2 2013 and has held it in 38 quarters since. The position peaked at $4.96M in Q4 2024. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Thrivent Financial for Lutherans held 29,960 shares of Teva Pharmaceuticals worth $896K as of Q1 2026.
  • Thrivent Financial for Lutherans bought 2,353 Teva Pharmaceuticals shares in Q1 2026, an estimated $75.7K.
  • Teva Pharmaceuticals made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #1947 holding.
  • Thrivent Financial for Lutherans first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
  • Thrivent Financial for Lutherans's Teva Pharmaceuticals position peaked at $4.96M in Q4 2024.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.